Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).

Stuschke M, Thomas M, Gröschel A, Sebastian M, Reck M, Hoffknecht P, Grah C, Spring L, Jänicke M, Lennartz C, Ludwig P, Groth A, Sadjadian P, Christopoulos P, Christoph DC, Griesinger F, Passlick B, Eberhardt WEE, CRISP Registry Group

Open source

DOI: 10.3390/cancers18142316
Published: 2026 Jul 18
Container: Cancers
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/cancers18142316,
  title = {Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).},
  author = {Stuschke M and Thomas M and Gröschel A and Sebastian M and Reck M and Hoffknecht P and Grah C and Spring L and Jänicke M and Lennartz C and Ludwig P and Groth A and Sadjadian P and Christopoulos P and Christoph DC and Griesinger F and Passlick B and Eberhardt WEE and CRISP Registry Group},
  year = {2026},
  journal = {Cancers},
  doi = {10.3390/cancers18142316},
  url = {https://doi.org/10.3390/cancers18142316}
}

RIS

TY  - JOUR
TI  - Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).
AU  - Stuschke M
AU  - Thomas M
AU  - Gröschel A
AU  - Sebastian M
AU  - Reck M
AU  - Hoffknecht P
AU  - Grah C
AU  - Spring L
AU  - Jänicke M
AU  - Lennartz C
AU  - Ludwig P
AU  - Groth A
AU  - Sadjadian P
AU  - Christopoulos P
AU  - Christoph DC
AU  - Griesinger F
AU  - Passlick B
AU  - Eberhardt WEE
AU  - CRISP Registry Group
PY  - 2026
JO  - Cancers
DO  - 10.3390/cancers18142316
UR  - https://doi.org/10.3390/cancers18142316
ER  -

APA

M, S., M, T., A, G., M, S., M, R., P, H., C, G., L, S., M, J., C, L., P, L., A, G., P, S., P, C., DC, C., F, G., B, P., WEE, E., & Group, C. R. (2026). Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).. Cancers. https://doi.org/10.3390/cancers18142316

Source records

pubmed · retrieved 2026-09-25T05:50:43.377Z